Curated News
By: NewsRamp Editorial Staff
May 13, 2026

Tonix Pharma to Present at Two Key Investor Conferences in May 2026

Discuss on Telegram View History of this news story on GitHub
Original Source

TLDR

  • Tonix Pharmaceuticals presents at two investor conferences in May 2026, offering opportunities to gain insight and competitive edge.
  • Tonix's TONMYA, approved for fibromyalgia, works via sublingual cyclobenzaprine; Phase 2 trials explore MDD and ASD applications.
  • Tonix addresses high unmet medical needs with treatments for fibromyalgia, migraine, Prader-Willi, Lyme disease, and transplant rejection.
  • TONMYA is the first new fibromyalgia treatment in 15 years, and Tonix is now testing it for depression and stress disorders.

Impact - Why it Matters

This news matters because Tonix Pharmaceuticals is addressing critical unmet medical needs with its recently approved fibromyalgia treatment TONMYA and a robust pipeline targeting CNS and immunology disorders. Investors and patients alike should watch for updates from these conferences, as they may provide insights into the company’s commercial strategy and clinical progress. The participation in high-profile conferences signals Tonix’s commitment to engaging with the investment community and advancing its therapies.

Summary

Tonix Pharmaceuticals (NASDAQ: TNXP), a fully integrated, commercial biotechnology company, has announced that its management team will participate in two upcoming investor conferences in May 2026. The events include the RBC Capital Markets Global Healthcare Conference on May 19 in New York and A.G.P.’s Annual Virtual Healthcare Conference on May 20. This news comes as Tonix continues to advance its pipeline of treatments for central nervous system (CNS) and immunology indications, focusing on areas of high unmet medical need.

Tonix’s flagship medicine, TONMYA™ (cyclobenzaprine HCl sublingual tablets 2.8mg), is the first new treatment for fibromyalgia in over 15 years and has recently been approved. The company’s CNS commercial infrastructure supports its marketed products, including acute migraine treatments Zembrace® SymTouch® and Tosymra®. Tonix is also exploring the potential of TONMYA in Phase 2 clinical trials for major depressive disorder and acute stress disorder. Additionally, the CNS pipeline includes TNX-2900, which is Phase 2 ready for Prader-Willi syndrome, a rare disease. In immunology, Tonix is advancing monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for kidney transplant rejection prevention.

To view the full press release, visit https://ibn.fm/ZZpG2. The latest news and updates relating to TNXP are available in the company’s newsroom at https://ibn.fm/TNXP. InvestorWire, a specialized communications platform, syndicated this press release. It is part of the Dynamic Brand Portfolio @ IBN, which provides access to a vast network of wire solutions, editorial syndication to 5,000+ outlets, press release enhancement, and social media distribution. InvestorWire is uniquely positioned to help companies reach a wide audience of investors and influencers.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Tonix Pharma to Present at Two Key Investor Conferences in May 2026

blockchain registration record for this content.